Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Pilot Study of the Efficacy and Safety of Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment

Next Previous
Trial Profile

A Phase 2 Pilot Study of the Efficacy and Safety of Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Apr 2022 Status changed from recruiting to completed, according to Results presented at the 113th Annual Meeting of the American Association for Cancer Research.
  • 13 Apr 2022 Results assessing combination of nivolumab and ipilimumab in eliminating the primary tumor in T1aN0M0 patients ineligible for surgical treatment, presented at the 113th Annual Meeting of the American Association for Cancer Research
  • 22 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top